RedHill Biopharma Ltd. ADR | Mutual Funds
Mutual Funds that own RedHill Biopharma Ltd. ADR
49,121
0.19%
0
1.54%
09/05/2018
Top Alpha Overseas Shares
48,000
0.19%
0
2.74%
06/28/2018
29,066
0.11%
0
0.41%
09/06/2018
15,101
0.06%
-448
0.64%
06/29/2018
I.B.I. Foreign Equity Liable
14,242
0.06%
0
0.24%
06/28/2018
Market Vectors - Israel ETF
7,198
0.03%
0
0.11%
09/05/2018
Yelin Lapidot Menayatit
7,067
0.03%
0
0.01%
04/30/2018
5,226
0.02%
869
0.45%
05/31/2018
Migdal Dikla Tel Aviv 100
3,050
0.01%
0
0.03%
12/31/2017
Edmond de Rothschild America Value
2,500
0.01%
0
0.28%
06/28/2018
| Address |
21 Ha'arba'a Street
Tel Aviv TA 64739
Israel
|
|
Employees
|
- |
| Website |
http://www.redhillbio.com |
| Updated |
07/08/2019 |
| RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. Its late clinical-stage pipeline includes TALICIA® (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria (NTM) infections; BEKINDA® (RHB-102) for acute gastroenteritis and gastritis and IBS-D; YELIVA® (ABC294640) for cholangiocarcinoma and targeting multiple other oncology, inflammatory and gastrointestinal indications; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and RHB-107, targeting cancer and inflammatory gastrointestinal diseases. |
